Board
Screen
Heat
Cal
Watch
News
Blog
TV
Home
/
PRAX
Home
/
PRAX

NASDAQ
$284.79
$284.79

Overview

Price performance
Low
$274.38
High
$287.66
Market closed. Last updated: Nov 4, 2026, 9:00 PM UTC
$
284.79
4.28 (1.53%)
Average, 50 days
$297.50
$314.53
Open
$286.63
Previous close
$280.51
52-week high
$392.70
Aug 20, 2026 (3 months ago)
52-week low
$159.74
Nov 7, 2025 (13 months ago)
78.28%

Valuation & Estimates

Earnings

Financials

Insider Trading

Peer Analysis

Insights & Activity

Market Cap
7.95B
Volume
304 596
Total Return (3M)
-8.15%
Total Return (1Y)
65.82%
5.43
Sector
Healthcare
Links
Tags
Healthcare
Biotechnology
NASDAQ
US
Website
praxismedicines.com
Socials
About
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.

Frequently asked questions

PRAX · Praxis Precision Medicines, Inc.

01What is Praxis Precision Medicines, Inc. stock price today?

The current price of PRAX is $284.79 — it has increased by 1.53% since the previous close. Data as of Nov 4, 2026.

02Is Praxis Precision Medicines, Inc. stock price growing?

PRAX is up 0.31% over the past week, down 3.63% over the past month and up 65.82% over the past year. The price is below its 200-day moving average of $314.53.

03What is PRAX stock forecast?

Analysts' average 12-month price target for PRAX is $611.69, which implies 114.79% upside from the current price. Individual estimates range from $162.00 to $1,201.00.

04What do analysts say about PRAX stock?

Of the 21 analysts covering Praxis Precision Medicines, Inc., 4 rate it a strong buy, 15 rate it a buy, 1 rates it a hold and 1 rates it a sell. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.

05What is Praxis Precision Medicines, Inc. market cap?

Praxis Precision Medicines, Inc. has a market capitalization of $7.95B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.

06What were Praxis Precision Medicines, Inc. earnings last quarter?

In its most recent quarterly report, Praxis Precision Medicines, Inc. posted a loss of $2.87 per share against an estimate of -$3.67, beating expectations by 21.80%. Upcoming reports are listed in the earnings calendar.

07Does Praxis Precision Medicines, Inc. pay dividends?

Praxis Precision Medicines, Inc. has not paid any dividends over the past year.

08How volatile is PRAX stock?

In the latest trading session PRAX moved between $274.38 and $287.66, a range of 4.66% of its current price.

09Should I invest in Praxis Precision Medicines, Inc. stock?

Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Praxis Precision Medicines, Inc. shows a buy rating today and a sell rating on the weekly timeframe. Technical ratings are indicators, not investment advice.

10What are PRAX stock 52-week high and low?

Over the past 52 weeks PRAX has traded between $159.74 and $392.70. The current price is 27.48% below its 52-week high.

Figures as of Nov 4, 2026. This information is provided for general purposes only and is not investment advice.